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Parkinson’s disease (PD) management has traditionally focused largely on motor symptoms. Deep brain stimulation (DBS) of the
subthalamicnucleus(STN)andglobuspallidusinternus(GPi)areeﬀectivetreatmentsformotorsymptoms.Nonmotorsymptoms
(NMSs) may also profoundly aﬀect the quality of life. The purpose of this pilot study was to evaluate NMS changes pre- and post-
DBS utilizing two recently developed questionnaires. Methods. NMS-Q (questionnaire) and NMS-S (scale) were administered
to PD patients before/after unilateral DBS (STN/GPi targets). Results. Ten PD patients (9 STN implants, 1 GPi implant) were
included. The three most frequent NMS symptoms identiﬁed utilizing NMS-Q in pre-surgical patients were gastrointestinal
(100%), sleep (100%), and urinary (90%). NMS sleep subscore signiﬁcantly decreased (−1.6 points ± 1.8, P = 0.03). The three
most frequent NMS symptoms identiﬁed in pre-surgical patients using NMS-S were gastrointestinal (90%), mood (80%), and
cardiovascular (80%). The largest mean decrease of NMS scores was seen in miscellaneous symptoms (pain, anosmia, weight
change, and sweating) (−7 points ± 8.7), and cardiovascular/falls (−1.9, P = 0.02). Conclusion. Non-motor symptoms improved
ontwoseparatequestionnairesfollowingunilateralDBSforPD.Futurestudiesareneededtoconﬁrmtheseﬁndingsanddetermine
their clinical signiﬁcance as well as to examine the strengths/weaknesses of each questionnaire/scale.
1.Introduction
The traditional approach to Parkinson’s disease (PD) pa-
tients has focused heavily on addressing motor symptoms
and on-oﬀ ﬂuctuations. Deep brain stimulation (DBS) of
the subthalamic nucleus (STN) and globus pallidus interna
(GPi) are potentially eﬀective treatments for these motor
types of symptoms. Nonmotor symptoms (NMSs), however,
are also common and debilitating and have been reported
in up to 28% of PD cases. NMS have also been reported
by some investigators as being more debilitating than motor
symptoms [1]. Two scales that have recently been used
to quantify nonmotor symptoms include the nonmotor
Symptoms Questionnaire (NMS-Q) and the Non-motor
Symptom Scale (NMS-S). Both scales were recently validated
by Chaudhuri and colleagues [2–4]. The purpose of this
pilot study was to evaluate NMS pre- and postoperatively
in unilateral PD cases utilizing these scales to determine
changes in overall NMS and to potentially guide a future
study.
2. Methods
Consecutive PD patients undergoing initial unilateral DBS
implantation at the University of Florida were screened. All
subjects were between the ages of 18 to 85, had the diagnosis
of idiopathic PD conﬁrmed by a movement disorders
specialist (utilizing UK Brain Bank criteria), and had a docu-
mented 30% or better improvement in motor performance2 Parkinson’s Disease
following levodopa administration (as measured by the
Uniﬁed Parkinson’s Disease Rating Scale Part III). Subjects
were excluded from DBS implantation and consequently
from this study if they had signiﬁcant and active psychiatric
disease as determined by a semistructured clinical interview
(SCID) or if neuropsychological testing revealed moderate
to severe cognitive impairment (DRS score of <130) or
dementia based on a neuropsychological proﬁle indicating
declines in multiple cognitive domains). The NMS-Q and
NMS-S scales were used to follow nonmotor symptoms pre-
and post-DBS. The NMS-Q was based on patient response
with “yes” and “no” questions. The NMS-S was a clinician-
based assessment questionnaire that both documents the
presence of the non-motor symptoms as well as their
frequency and duration.
Utilizing the NMS-Q form, the subsets were divided (in
an attempt to derive comparisons to the NMS-S) as follows:
q u e s t i o n s1 ,3 ,4 – 7w e r eg r o u p e du n d e rt h egastrointestinal
symptoms subset, questions 8-9 were grouped under the
urinary symptoms subset, questions 2, 10-11 and 27-28
were grouped under the miscellaneous symptoms subset,
questions 12-13 and 15 were grouped under the cognition
symptoms subset, questions 16-17 were grouped under
the mood symptoms subset, questions 18-19 were grouped
under the sexual dysfunction symptoms subset, questions 20-
21 were grouped under the cardiovascular/falls symptoms
subset, questions 22–26 were grouped under the sleep
symptoms subset, and questions 14, 29-30 were grouped
under perceptual symptoms subset. A patient was counted as
having the symptom if (s)he has a positive answer in at least
one of the questions in the corresponding subset.
Utilizing the NMS-S form, the subsets were divided
as follows: questions 1-2 were grouped under the cardio-
vascular/falls symptom subset; questions 3–7 were grouped
under the sleep/fatigue symptoms subset; questions 8–14
were grouped under the mood symptoms subset; questions
15–17 were grouped under the perceptual symptoms subset;
questions18–20weregroupedunderthecognitionsymptoms
subset; questions 21–23 were grouped under the gastroin-
testinal symptoms subset; questions 24–26 were grouped
under the urinary symptoms subset; questions 27-28 were
grouped under the sexual dysfunction symptoms subset;
questions 29–32 were grouped under the miscellaneous
symptoms subset.
The primary analysis included the changes observed at
baseline versus 6 months on the total NMS-Q and NMS-
S scales. As secondary outcomes we examined subscores;
however, sample sizes limited the overall interpretation.
3. Results
Ten PD patients (9 STN implants, 1 GPi implant) were
included in this pilot study. All patients were screened and
consented for research participation in the Movement Disor-
dersCenterdatabase(INFORM-PD).Themeanagewas66.1
years ±7.8, and the mean disease duration was 9.9 years ±3.
The average time from preoperative to postoperative testing
was 12.1 months ±7.3 (range 1–25 months). The average
change of UPDRS motor score was −6.4 points ±13.1.
The primary analysis for the NMS-Q revealed that the
total score for NMS symptoms (total possible score 30
points) improved by an average of −3.7 points ±4.3 (P =
0.03) (Table 1). Secondary analyses of the sample were then
performed. The three most prevalent NMS symptoms iden-
tiﬁed in pre-surgical patients were gastrointestinal (100%),
sleep(100%),andurinarysymptoms(90%).Postoperatively,
the three most prevalent NMS symptoms were sleep (90%),
urinary (90%), and cognition (60%) subsets. The largest
mean decrease of NMS scores were sleep (−1.6 points ±1.8,
P = 0.03), gastrointestinal (−0.8 points ±1.1, P = 0.09),
and cardiovascular/falls (−0.5 ± 1.0, P = 0.23) subsets. Only
the sleep subscore in this small sample size reached statistical
signiﬁcance. Some other NMS categories also improved
(but did not reach statistical signiﬁcance) postoperatively
including sexual dysfunction (−0.22 points ±0.83), mood
(−0.2 points ±0.8), and miscellaneous (unexplained pain,
excessive sweating, leg swelling) items (−0.5 points ±1.8).
Miscellaneous symptom scores increased (50% to 60%),
while urinary scores were unchanged (90%).
Using the NMS-S (total possible score 384 points), the
primary analysis revealed that the NMS scores improved
by an average of −38.5 points ±30.9 (P = 0.01). A
secondary analysis then revealed that three most prevalent
NMS symptoms identiﬁed in pre-surgical patients were
gastrointestinal (90%), mood (80%), and cardiovascular
(80%) symptoms. Postoperatively, the most prevalent NMS
symptoms were urinary (80%), mood (70%), sexual (60%),
and gastrointestinal (60%) symptoms. The largest mean
decrease of NMS scores was in the categories of mood (−9.3
points ±13.8), sleep (−9 points ±13.3), and miscellaneous
(−7 points ±8.7). Only miscellaneous symptoms (pain,
anosmia, weight change, and sweating) (−7 points ±8.7),
and cardiovascular/falls (−1.9, P = 0.02) reached statistical
signiﬁcance (Tables 1 and 2).
Reports of sexual symptoms increased slightly from
55.6% preoperatively to 60% postoperatively.
4. Discussion
Both scales we administered revealed an improvement in
non-motor symptoms following unilateral DBS, although
the sample size limited our understanding of speciﬁc symp-
toms that may change. Sleep was, however, one feature that
emerged as potentially important. Sleep impairment has
been reported recently by several prepost-DBS studies, and
this may be supported by our data [5]. Changes revealed in
cardiovascular status, autonomic features, or falling may also
be reported by some patients undergoing DBS; however, the
small sample size of this study make interpretation diﬃcult.
Nonmotor symptoms are common in PD patients and
can be important in determining overall quality of life
[6]. The eﬀects of DBS on NMS symptoms in advanced
PD cohorts have not been entirely clariﬁed [7]. In a
study by Witjas and colleagues, 40 PD patients implanted
with bilateral STN DBS experienced signiﬁcant beneﬁts
with sensory/painful ﬂuctuations, dysautonomia (excessive
sweating), and cognitive ﬂuctuations [8]. In another studyParkinson’s Disease 3
Table 1:Changesinnonmotorsymptom(NMS)scorefromquestionnaire.Theleft-sidedgroupshowspercentofsubjectswhohadapositive
answer in at least one of the questions in the corresponding subset. The right-sided group shows changes in NMS score as represented by
the diﬀerence in total score. Improvements of NMS scores prepost-deep brain stimulation surgery were signiﬁcant. Also, sleep improved
prepost-DBS (P = 0.03).
NMS
Frequency of NMS reported NMS Total point
(% present) diﬀerence
Pre-DBS Post-DBS P Value∗ Mean SD P Value∗∗
NMS-Q — — — −3.70 4.27 0.03
Gastrointestinal 100.0% 50.0% NA −0.80 1.14 0.09
Urinary 90.0% 90.0% 1.00 0.00 0.67 1.00
Miscellaneous 50.0% 60.0% 0.66 −0.50 1.84 0.45
Perceptual 30.0% 30.0% 1.00 0.20 0.63 0.63
Attention/memory 70.0% 60.0% 0.56 −0.10 0.62 0.81
Mood 60.0% 50.0% 0.56 −0.20 0.79 0.75
Sexual 55.6% 50.0% 1.00 −0.22 0.83 0.75
Cardiovascular/falls 80.0% 50.0% 0.18 −0.50 0.97 0.23
Sleep 100.0% 90.0% NA −1.60 1.84 0.03
∗: P-values based on McNemar’s test.
∗∗: P-values based on Wilcoxon signed rank sum test.
Table 2: Changes in nonmotor symptoms (NMS) scale. The left-sided group shows prepost-DBS change in prevalence of NMS symptoms.
The right-sided group shows changes in NMS score as a diﬀerence in total score. Improvements of NMS scores pre-post deep brain
stimulationsurgeryweresigniﬁcant(P = 0.01).Meanscoresinmiscellaneoussymptoms(P = 0.03)aswellascardiovascular/falls(P = 0.02)
symptoms had signiﬁcant improvement. Prevalence of CV/falls was also signiﬁcantly diﬀerent between pre- and post-DBS.
NMS
Frequency of NMS reported NMS total point
(% present) diﬀerence
Pre-DBS Post-DBS P value∗ Mean SD P value∗∗
NMS-S — — — −38.50 30.94 0.01
Gastrointestinal 90.0% 60.0% 0.18 −0.30 7.33 0.93
Urinary 70.0% 80.0% 0.56 −3.30 6.11 0.14
Miscellaneous 70.0% 40.0% 0.08 −7.00 8.69 0.03
Perceptual 20.0% 20.0% 1.00 0.00 1.25 1.00
Attention/memory 70.0% 60.0% 0.56 −3.50 8.20 0.30
Mood/cognition 80.0% 70.0% 0.56 −9.30 13.78 0.09
Sexual 55.6% 60.0% 1.00 −4.78 7.29 0.13
Cardiovascular/falls 80.0% 30.0% 0.03 −1.90 2.08 0.02
Sleep/fatigue 100.0% 100.0% NA −8.95 13.28 0.13
∗: P-values based on McNemar’s test.
∗∗: P-values based on Wilcoxon signed rank sum test.
by Zibetti and colleagues, sleep and constipation were the
only symptoms that improved following bilateral STN DBS
surgery in 36PD patients [9]. Our pilot data, although
derived from a small number of patients, utilized two
recently validated NMS questionnaires and did point to
improvements in NMS and particularly improvements in
sleep.
Within our cohort, sleep, gastrointestinal, and cardio-
vascular/falls improved the most when using the NMS-Q
while mood, sleep, and miscellaneous symptoms improved
when employing the NMS-S. A possible explanation for the
diﬀerences in the two scales may have been the number
of symptoms attributed to each subscore. In the NMS-Q
there were 2 questions that comprised the mood subset,
while in the NMS-S, there were 7. In another example, the
NMS-Qgastrointestinalsubsetwascomposedof9questions,
while, in the NMS-S scale, it was only 3. Finally, mood
symptomsweremorecommonlyreportedintheNMS-S,but
not in the NMS-Q. Devoting more questions to a particular
symptom could increase the sensitivity of any scale for a
particular area, and this may have biased our dataset. While
the changes in overall score were close between the two scales
(∼10% improvement), one might hypothesize for future
investigations that greater information may be derived from
the NMS-S (when compared to the NMS-Q) as it queries
both frequency and severity of symptoms.
The major limitation of this pilot study was the sample
size. Our analysis yielded results which reached signiﬁcance4 Parkinson’s Disease
when employing the total scores of the scales (NMS-Q, P =
0.03; NMS-S, P = 0.01) but yielded less signiﬁcant and
impressive results when parceling subitems. Further, it is not
clearwhatdegreeofchangeintheseNMSquestionnaireswill
prove clinically signiﬁcant. We emphasize that there was a
small sample size used in this pilot study, therefore, results
should be considered preliminary and speculative. Future
studies should focus on both STN and GPi (our sample
was small for GPi) and should include both unilateral and
bilateral cases preferably with a larger sample size and longer
clinical followup. Based on the preliminary data, there is
reason to believe that NMS have the potential to change pre-
and post-unilateral DBS, and better understanding NMS
will help us to achieve greater beneﬁts and more realistic
expectations from our DBS patients.
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